JNMT
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shih, W.-J.
Right arrow Articles by Milan, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shih, W.-J.
Right arrow Articles by Milan, P. P.
Journal of Nuclear Medicine Technology Volume 32, Number 1, 2004 19-21
© 2004 by Society of Nuclear Medicine

IMAGING

99mTc-Depreotide Chest SPECT Demonstrates Pulmonary Metastases from Renal Cell Carcinoma

Wei-Jen Shih, MD;1,2, Ramon A.L. Romero, MD;3,4, Mullet Timothy, MD;3,4 and Primo P. Milan, MD5

1 Nuclear Medicine Service, VA Medical Center, Lexington, Kentucky;
2 Department of Diagnostic Radiology, College of Medicine, University of Kentucky, Lexington, Kentucky;
3 Surgical Service, VA Medical Center, Lexington, Kentucky;
4 Department of Surgery, College of Medicine, University of Kentucky, Lexington, Kentucky;
5 Radiology Service, VA Medical Center, Lexington, Kentucky

99mTc-Depreotide has been used on single pulmonary nodules to identify somatostatin receptor-positive lung cancer. We report that pulmonary metastases of a 78-y-old man with postradical nephrectomy for renal cell carcinoma were detected by 99mTc-depreotide chest SPECT. Thus, 99mTc-depreotide chest SPECT can be used to diagnose secondary lung cancer, such as pulmonary metastases from renal cell carcinoma with somatostatin receptor-positive tumor, other than primary lung cancer. Depending on whether the 99mTc-depreotide was positive for pulmonary metastases, the patient underwent an appropriate therapy without further invasive procedures.

Key Words: oncology; SPECT; renal; 99mTc; somatostatin receptor






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE JOURNAL OF NUCLEAR MEDICINE JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
Copyright © 2004 by the Society of Nuclear Medicine Technologist Section.